Last reviewed · How we verify

ESL — Competitive Intelligence Brief

ESL (ESL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Voltage-gated sodium channel blocker; anticonvulsant. Area: Neurology.

marketed Voltage-gated sodium channel blocker; anticonvulsant Voltage-gated sodium channels (Nav) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ESL (ESL) — Bial - Portela C S.A.. ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability and stabilizes seizure threshold.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ESL TARGET ESL Bial - Portela C S.A. marketed Voltage-gated sodium channel blocker; anticonvulsant Voltage-gated sodium channels (Nav)
Oxcarbazepine XR Oxcarbazepine XR Supernus Pharmaceuticals, Inc. phase 3 Anticonvulsant; voltage-gated sodium channel blocker Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Voltage-gated sodium channel blocker; anticonvulsant class)

  1. Bial - Portela C S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ESL — Competitive Intelligence Brief. https://druglandscape.com/ci/esl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: